Emerging drug therapies for benign prostatic hyperplasia

Expert Opinion on Emerging Drugs
Travis L Bullock, Gerald Andriole

Abstract

Benign prostatic hyperplasia (BPH) is the nonmalignant enlargement of the prostate gland caused by increases in number of both epithelial and stromal cells. Clinically, BPH leads to voiding dysfunction, which is most often referred to as lower urinary tract symptoms (LUTS). Historically, the only treatments for LUTS due to BPH were watchful waiting or surgery (transurethral or open prostatectomy). However, over the last 20 years medical therapy has taken a prominent role in the management of BPH. Current medical treatments for BPH include alpha-adrenergic receptor antagonists, inhibitors of the 5-alpha reductase enzyme and various phytotherapies. These agents are generally effective and safe; however, many patients are unable to tolerate the side effects or are refractory to medical management and require surgery. In light of this, many potential new therapies for the treatment of BPH are under development. Some represent a variation of current treatments, whereas others target novel molecular pathways within the prostate. The aim of this review is to examine current pharmacotherapies as well as to highlight emerging drugs that may improve our treatment of patients with LUTS secondary to BPH.

References

Oct 22, 1992·The New England Journal of Medicine·G J GormleyJ S Tenover
Aug 1, 1987·British Journal of Urology·R S KirbyE J Milroy
Sep 1, 1984·The Journal of Urology·S J BerryL L Ewing
Apr 18, 2001·European Urology·P E Van Kerrebroeck
May 23, 2002·World Journal of Urology·Klaus Höfner, Udo Jonas
Jul 12, 2002·The Urologic Clinics of North America·Elliot Fagelman, Franklin C Lowe
Jul 18, 2002·Nature Reviews. Drug Discovery·Mitchell A Miller
Sep 28, 2002·Urology·Claus G RoehrbornUNKNOWN ARIA3001 ARIA3002 and ARIA3003 Study Investigators
Oct 3, 2002·Nature Medicine·Alan Dove
Jun 26, 2003·The New England Journal of Medicine·Ian M ThompsonCharles A Coltman
Dec 19, 2003·The New England Journal of Medicine·John D McConnellUNKNOWN Medical Therapy of Prostatic Symptoms (MTOPS) Research Group
Sep 15, 2004·European Urology·Frans DebruyneUNKNOWN ARIA3001, ARIA3002 and ARIB3003 Study Investigators
Feb 10, 2006·The New England Journal of Medicine·Stephen BentAndrew L Avins
Apr 1, 2002·World Journal of Urology·Klaus Höfner, Udo Jonas

❮ Previous
Next ❯

Citations

Apr 20, 2011·Prostate Cancer and Prostatic Diseases·J Y KangH-L Lee
Apr 2, 2011·Indian Journal of Pharmacology·Neelima Dhingra, Deepak Bhagwat
Mar 23, 2011·Toxicon : Official Journal of the International Society on Toxinology·Arhamatoulaye MaïgaNicolas Gilles
Jan 26, 2011·European Journal of Pharmacology·Justyna CiolekNicolas Gilles
Mar 17, 2016·Nephro-urology Monthly·Maryam SarbishegiFereydoon Sargolzaei Aval
Jan 4, 2007·The Journal of Pathology·N SampsonP Berger
Jan 24, 2012·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·In-Sik ShinHyeun-Kyoo Shin
Jun 16, 2015·Chinese Journal of Natural Medicines·Hai-Nan ShenTao Wang
Jul 12, 2016·Annals of Medical and Health Sciences Research·A S Elhwuegi
Sep 26, 2017·Biological & Pharmaceutical Bulletin·Charith Ub WijerathneHyo-Jung Kwun
Sep 30, 2017·Phytotherapy Research : PTR·Bahaa Al-TradGhada Al Omari
Nov 21, 2018·International Journal of Immunopathology and Pharmacology·Changlei YaoWeitao Zhang
Nov 2, 2018·Biological & Pharmaceutical Bulletin·Hee-Seon ParkHyo-Jung Kwun
Feb 7, 2019·Pharmaceutical Biology·Bong Kyun ParkSe Chan Kang
Feb 18, 2017·Phytotherapy Research : PTR·Olubukola Oyebimpe AkanniOluwatosin Adekunle Adaramoye
Jul 11, 2012·Clinical Trials : Journal of the Society for Clinical Trials·Franklin G Miller
Apr 1, 2014·Molecular Medicine Reports·Mee-Young LeeHyeun-Kyoo Shin
Dec 8, 2016·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Jing ChenJin-Lan Ruan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.